A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.
News|Articles|December 15, 2023
Rheumatoid Arthritis Quiz: RA Treatment and the Risk of Serious Cardiovascular Events
Author(s)Ingrid Torjesen
Rheumatoid arthritis and its treatment can increase the risk of cardiovascular events. Test your knowledge of how risk of serious cardiovascular events is affected by RA treatments with this quiz.
Advertisement
Which of the following rheumatoid arthritis treatments is believed to be cardioprotective?
Advertisement
Related to this article
Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.
Approved US PFIC drugs treat pruritus. The researcher behind a therapy targeting BSEP on diagnosis, data, and what comes next.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Hematology in September 2026: ASH raises ferritin thresholds for iron deficiency, plus marstacimab in hemophilia and curative SCD care.
Strong recommendations cover carvedilol or banding for varices, semiannual HCC surveillance, vaccines, and smoking cessation.
April Armstrong, MD, MPH, discusses 1-year RELIEVE-AD-PEDs data on rapid, sustained dupilumab disease control in adolescents with atopic dermatitis.
Advertisement
Advertisement
Trending on HCPLive
1
RELIEVE-AD-PEDs: Dupilumab Sustains Adolescent Atopic Dermatitis Control at 1 Year
2
3 Hematology Headlines You Missed in September 2026
3
Conservative Therapy in Fibrillary GN: A Four-Drug Kidney-Protective Approach
4
Top Reason for Leaving HAE Attacks Untreated, Survey Finds
5